CRBP

Corbus Pharmaceuticals Holdings Inc

3.91

Nov 02 • 3:59 PM ET -0.30 (-7.23%)

3.91

Aftermarket • 7:30 PM ET -0.00 (-0.13%)

Healthcare Biotechnology USA Micro NASD

Peers: WHWK KYNB PYXS STRO MGNX AKTS ALT SKYE VKTX ARTL

| Held by: VTI IWM VXF VTWO IWN DFAS FESM IWC DFMC AVSC

Index	RUT
Market Cap	75.72M
Enterprise Value	-37.96M
Income	-101.90M
Sales	0.00M
Book/sh	5.48
Cash/sh	6.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	36
IPO	Oct 27, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.71
P/C	0.64
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.71
Current Ratio	5.71
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-6.18
EPS next Y	-5.55
EPS next Q	-1.27
EPS this Y	5.12%
EPS next Y	0.92%
EPS next 5Y	1.15%
EPS past 3/5Y	16.56% 32.70%
Sales past 3/5Y	- -
EPS Y/Y TTM	-29.66%
Sales Y/Y TTM	-
EPS Q/Q	-25.12%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-43.79% -

Insider Own	10.22%
Insider Trans	-18.51%
Inst Own	65.67%
Inst Trans	4.15%
ROA	-80.85%
ROE	-95.58%
ROIC	-96.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.26%
SMA50	-44.43%
SMA200	-54.47%
Trades

Shs Outstand	18.67M
Shs Float	17.36M
Short Float	15.64%
Short Ratio	2.94
Short Interest	2.71M
52W High	12.88 -69.61%
52W Low	3.87 1.16%
Volatility	6.15% 7.78%
ATR (14)	0.38
RSI (14)	22.41
Beta	2.81
Rel Volume	0.73
Avg Volume	922.49K
Volume	674,229

Perf Week	-1.88%
Perf Month	-36.13%
Perf Quarter	-58.35%
Perf Half Y	-62.79%
Perf YTD	-51.90%
Perf Year	-67.78%
Perf 3Y	-19.61%
Perf 5Y	-87.57%
Perf 10Y	-97.42%
Recom	1.00
Target Price	33.12
Prev Close	4.22
Price	3.91
Change %	-7.23%

Consensus

Strong Buy

Avg. Price Target

$33.12

Implied Upside

+746.0%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 29, 2026	Initiated	GGuggenheim	Buy	$45	+1,049.4%
Jul 30, 2025	Resumed	RB. Riley Securities	Buy	$28	+615.2%
Feb 28, 2025	Initiated	WWilliam Blair	Outperform
Dec 02, 2024	Initiated	PPiper Sandler	Overweight
Jul 30, 2024	Initiated	WWedbush	Outperform	$85	+2,071.1%
Jul 22, 2024	Resumed	HH.C. Wainwright	Buy	$80	+1,943.4%
Jun 26, 2024	Initiated	RB. Riley Securities	Buy	$85	+2,071.1%
Jun 03, 2024	Reiterated	OOppenheimer	Outperform	$60 → $80	+1,943.4%
May 13, 2024	Initiated	RRBC Capital Mkts	Outperform	$77	+1,866.8%
Mar 06, 2024	Upgrade	JJefferies	Hold → Buy	$4 → $46	+1,075.0%
Sep 08, 2020	Downgrade	RROTH Capital	Buy → Neutral	$40 → $3	-23.4%
Sep 08, 2020	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform
Sep 08, 2020	Downgrade	JJefferies	Buy → Hold	$18 → $2.50	-36.1%
Sep 08, 2020	Downgrade	BBTIG Research	Buy → Neutral
Jul 07, 2020	Initiated	RROTH Capital	Buy	$40	+921.7%
Jun 17, 2020	Initiated	BBTIG Research	Buy	$22	+461.9%
Mar 26, 2020	Initiated	NNomura	Buy	$12	+206.5%
Apr 05, 2019	Initiated	JJefferies	Buy
Mar 20, 2019	Initiated	OOppenheimer	Outperform	$28	+615.2%
Jan 11, 2019	Reiterated	CCantor Fitzgerald	Overweight	$36 → $38	+870.6%

Oct-22-26 08:00AM	Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week 2026 (GlobeNewswire)
Sep-29-26 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer (GlobeNewswire)
Sep-14-26 09:28AM	Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data (InvestorsHub)
07:00AM	Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity (GlobeNewswire)
Sep-11-26 04:01PM	Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity (GlobeNewswire)
10:00AM	Loading…
Aug-17-26 10:00AM	Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 08:12AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
08:00AM	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-04-26 08:30AM	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity (GlobeNewswire) +5.38%
Jul-28-26 08:00AM	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer (GlobeNewswire)
Jul-06-26 08:00AM	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer (GlobeNewswire)
May-26-26 07:00AM	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers (GlobeNewswire) -30.31%
May-21-26 08:00AM	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call (GlobeNewswire) +18.29%
May-14-26 08:00AM	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors (GlobeNewswire)
May-13-26 07:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.30%
08:06AM	Loading…
May-12-26 08:06AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
08:00AM	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-26 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 (GlobeNewswire)
Apr-29-26 09:42AM	Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls (The Fly)
Apr-22-26 08:00AM	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 (GlobeNewswire)
Apr-14-26 08:00AM	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity (GlobeNewswire)
Apr-07-26 08:00AM	Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer (GlobeNewswire)
Mar-18-26 08:00AM	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit (GlobeNewswire) -6.02%
Mar-09-26 07:48AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +19.23%
07:30AM	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-26-26 03:08AM	Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead (MarketBeat) +6.18%
Feb-12-26 08:00AM	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire)
Jan-05-26 07:30AM	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 11:16AM	2 Pharma Stocks Pop on Strong Obesity Drug Trial Results (Schaeffer's Research) -5.65%
07:00AM	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (GlobeNewswire)
04:01PM	Loading…
Dec-10-25 04:01PM	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (GlobeNewswire)
Nov-12-25 08:09AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +7.39%
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-06-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 02:40AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -26.09%
Oct-30-25 04:31PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Oct-18-25 03:00AM	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 (GlobeNewswire)
Oct-14-25 08:00AM	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium (GlobeNewswire)
Sep-22-25 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 (GlobeNewswire)
Sep-16-25 08:00AM	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +9.61%
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks) -6.33%
Aug-05-25 08:11AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 08:00AM	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress (GlobeNewswire)
Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Oct 29 '26	Sale	4.10	425,000	1,742,755	1,919,971	Nov 02 04:05 PM
Ben Yong	Director	Sep 14 '26	Sale	7.84	2,000	15,683	9,383	Sep 15 04:59 PM
Saxena Nishant C	Chief Business Officer	Aug 11 '26	Buy	9.63	2,600	25,036	77,900	Aug 12 04:30 PM
Cohen Yuval	Chief Executive Officer	Aug 07 '26	Sale	10.08	17,000	171,396	157,316	Aug 10 04:30 PM
Moran Sean F.	Chief Financial Officer	Aug 07 '26	Sale	10.08	12,000	120,971	84,694	Aug 10 04:30 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	12,000	120,971		Aug 07 04:23 PM
Stifel, Nicolaus & Company, In	Officer	Aug 07 '26	Proposed Sale	10.08	17,000	171,396		Aug 07 04:04 PM
Smethurst Dominic	Officer	Jul 27 '26	Proposed Sale	9.20	23,025	211,818		Jul 27 04:06 PM
Kung Winston	Director	Jun 10 '26	Sale	7.91	2,026	16,033	12,140	Jun 11 04:30 PM
Altmeyer Anne	Director	Jun 10 '26	Sale	7.91	2,412	19,088	7,579	Jun 11 04:30 PM
Jenkins John Kenneth	Director	Jun 10 '26	Sale	7.91	4,800	37,986	3,833	Jun 11 04:30 PM
Saxena Nishant C	Chief Business Officer	Jun 03 '26	Buy	7.58	9,000	68,220	75,300	Jun 03 05:36 PM
Saxena Nishant C	Chief Business Officer	Jun 02 '26	Buy	7.33	4,500	32,998	66,300	Jun 03 05:36 PM
Smethurst Dominic	Chief Medical Officer	Mar 02 '26	Sale	8.30	6,097	50,601	89,790	Mar 04 04:30 PM
Smethurst Dominic	Officer	Mar 02 '26	Proposed Sale	8.30	6,097	50,601		Mar 02 04:08 PM
Hodgson Ian	Chief Operating Officer	Feb 17 '26	Sale	7.38	847	6,253	51,080	Feb 18 04:32 PM
Moran Sean F.	Chief Financial Officer	Feb 13 '26	Sale	7.78	4,701	36,588	96,694	Feb 18 04:31 PM
Cohen Yuval	Chief Executive Officer	Feb 13 '26	Sale	7.78	13,871	107,952	174,316	Feb 18 04:30 PM
Cohen Yuval	Officer	Feb 13 '26	Proposed Sale	40.63	20,000	812,600		Feb 13 04:02 PM
Smethurst Dominic	Chief Medical Officer	Feb 03 '26	Sale	8.09	3,285	26,575	95,887	Feb 04 04:25 PM
Hodgson Ian	Chief Operating Officer	Feb 03 '26	Sale	8.09	2,415	19,537	51,927	Feb 04 04:24 PM
Cormorant Asset Management, LP	10% Owner	Dec 11 '25	Sale	11.46	30,029	344,012	2,344,971	Dec 15 04:18 PM

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CEO & DirectorDr. Yuval Cohen Ph.D.

M.B.A.Mr. Sean F. Moran CPA

Ph.D.Dr. Ian Hodgson B.Sc.

M.S.Mr. G. Scott Goeken J.D.

Vice President of Human ResourcesMs. Christina Bertsch M.A.

Open in Screener

DRUG

Bright Minds Biosciences Inc

26.20

Nov 02 • 3:59 PM ET -28.78 (-52.35%)

24.00

Aftermarket • 7:30 PM ET -2.20 (-8.40%)

Healthcare Biotechnology USA Micro NASD

DRUG Bright Minds Biosciences Inc daily Stock Chart

Peers: STOK XENE PRAX RAPP OVID SPTX HELP GHRS MPLT NMRA

| Held by: IWM IWO FESM PSIL VTWO IWC GWX VTWG AVSC GSSC

Index	RUT
Market Cap	258.44M
Enterprise Value	41.52M
Income	-17.75M
Sales	0.00M
Book/sh	21.99
Cash/sh	22.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	25
IPO	Mar 22, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.19
P/C	1.19
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	121.97
Current Ratio	121.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.08
EPS next Y	-6.12
EPS next Q	-1.16
EPS this Y	-108.64%
EPS next Y	-125.12%
EPS next 5Y	-
EPS past 3/5Y	35.51% -35.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	-120.28%
Sales Y/Y TTM	-
EPS Q/Q	67.03%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	86.51% -

Insider Own	23.39%
Insider Trans	0.00%
Inst Own	83.43%
Inst Trans	2.93%
ROA	-13.80%
ROE	-13.93%
ROIC	-8.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-49.17%
SMA50	-54.95%
SMA200	-64.08%
Trades

Shs Outstand	9.86M
Shs Float	7.56M
Short Float	10.98%
Short Ratio	6.42
Short Interest	0.83M
52W High	123.75 -78.83%
52W Low	47.23 -44.53%
Volatility	5.61% 6.96%
ATR (14)	5.82
RSI (14)	22.75
Beta	-4.82
Rel Volume	14.14
Avg Volume	129.20K
Volume	1,826,841

Perf Week	-48.72%
Perf Month	-48.31%
Perf Quarter	-66.13%
Perf Half Y	-68.53%
Perf YTD	-66.43%
Perf Year	-52.15%
Perf 3Y	1855.22%
Perf 5Y	-27.72%
Perf 10Y	-
Recom	1.11
Target Price	127.09
Prev Close	54.98
Price	26.20
Change %	-52.35%

Consensus

Strong Buy

Avg. Price Target

$127.09

Implied Upside

+385.1%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	WWolfe Research	Outperform	$150	+472.5%
Apr 13, 2026	Initiated	JJefferies	Buy	$145	+453.4%
Sep 08, 2025	Initiated	BBTIG Research	Buy	$72	+174.8%
May 13, 2025	Initiated	TTD Cowen	Buy
May 07, 2025	Initiated	CChardan Capital Markets	Buy	$80	+205.3%
Jan 23, 2025	Initiated	PPiper Sandler	Overweight	$93	+255.0%
Jan 10, 2025	Initiated	HH.C. Wainwright	Buy	$85	+224.4%
Jan 10, 2025	Initiated	CCantor Fitzgerald	Overweight
Nov 26, 2024	Initiated	RRobert W. Baird	Outperform	$75	+186.3%

Today 10:51AM	Bright Minds Biosciences Faces Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Study (InvestorsHub) -52.35%
10:02AM	Bright Minds stock plunges as FDA halts epilepsy trial (Investing.com)
07:30AM	Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies (GlobeNewswire)
Sep-30-26 05:30PM	Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference (GlobeNewswire)
Sep-04-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
12:31PM	Loading…
Aug-28-26 12:31PM	What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? (Quartz)
May-26-26 07:18PM	Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-25-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.00%
Feb-18-26 09:31PM	Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials (Insider Monkey) +7.20%
Feb-17-26 10:09AM	Canadian Securities Exchange Reports January 2026 Performance Figures (TMX Newsfile) +7.72%
Jan-09-26 11:56AM	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering (GlobeNewswire)
Jan-07-26 09:33PM	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock (GlobeNewswire) -6.22%
Jan-06-26 04:00PM	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering (GlobeNewswire) +16.50%
07:16AM	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) (GlobeNewswire)
04:30PM	Loading…
Jan-05-26 04:30PM	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 (GlobeNewswire)
Nov-26-25 08:55AM	Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why (Zacks)
Nov-25-25 04:30PM	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting (GlobeNewswire) +8.37%
09:55AM	Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet (Zacks)
Nov-17-25 05:29PM	Why Bright Minds Biosciences Stock Topped the Market on Monday (Motley Fool)
06:50AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) (GlobeNewswire)
Nov-06-25 06:30AM	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH (GlobeNewswire) +7.55%
Oct-30-25 06:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Oct-15-25 08:50AM	Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-18-25 09:55AM	Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade (Zacks) +12.23%
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-04-25 08:30AM	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model (GlobeNewswire)
Sep-02-25 09:55AM	Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect? (Zacks)
03:50AM	Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy (Insider Monkey)
Aug-25-25 08:00AM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.14%
08:00AM	Loading…
May-28-25 08:00AM	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 (GlobeNewswire)
May-13-25 08:30AM	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 (GlobeNewswire)
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
Apr-28-25 08:00AM	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study (GlobeNewswire)
Apr-16-25 12:09PM	Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (Seeking Alpha)
Mar-04-25 08:00AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research (GlobeNewswire) -7.70%
Feb-24-25 06:50AM	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March (GlobeNewswire)
Jan-07-25 06:50AM	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Apr 28 '26	Sale	89.50	109,331	9,785,124	950,000	Apr 30 04:07 PM

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Co-FounderMr. Ian McDonald

C.A.Mr. Ryan E. S. K. Cheung B.Com.

Ph.D.Dr. Jan Torleif Pedersen M.Sc.

COO & Senior Scientific OfficerMr. Alex Vasilkevich

Ph.D.Dr. Emer Leahy M.B.A.

Open in Screener

EYPT

EyePoint Inc

0.3748

Nov 02 • 3:59 PM ET +0.0264 (7.58%)

0.3744

Aftermarket • 7:32 PM ET -0.0004 (-0.11%)

Healthcare Biotechnology USA Nano NASD

Peers: OCUL KOD SGP FDMT OTLK RGNX OCS SRZN BLTE TARS

| Held by: VTI VXF VTWO IWM VHT XPH VTWG IWO SCHA DFAS

Index	RUT
Market Cap	32.32M
Enterprise Value	-125.78M
Income	-306.64M
Sales	2.79M
Book/sh	1.96
Cash/sh	2.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	214
IPO	Jan 27, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	11.58
P/B	0.19
P/C	0.18
P/FCF	-
EV/EBITDA	-
EV/Sales	-45.08
Quick Ratio	4.46
Current Ratio	4.50
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-3.74
EPS next Y	-2.14
EPS next Q	-0.93
EPS this Y	-14.57%
EPS next Y	41.22%
EPS next 5Y	27.67%
EPS past 3/5Y	-4.94% 2.18%
Sales past 3/5Y	-8.83% -1.85%
EPS Y/Y TTM	-39.78%
Sales Y/Y TTM	-94.63%
EPS Q/Q	-28.45%
Sales Q/Q	-90.49%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-10.82% 14.45%

Insider Own	6.38%
Insider Trans	0.10%
Inst Own	123.66%
Inst Trans	9.60%
ROA	-115.86%
ROE	-148.70%
ROIC	-164.66%
Gross Margin	-18.29%
Oper. Margin	-11365.22%
Profit Margin	-10994.73%
SMA20	-77.42%
SMA50	-87.95%
SMA200	-96.56%
Trades

Shs Outstand	84.98M
Shs Float	80.71M
Short Float	26.34%
Short Ratio	2.38
Short Interest	21.26M
52W High	19.11 -98.04%
52W Low	0.34 8.76%
Volatility	10.23% 10.38%
ATR (14)	0.24
RSI (14)	16.54
Beta	1.85
Rel Volume	0.71
Avg Volume	8.93M
Volume	6,327,753

Perf Week	2.49%
Perf Month	-88.47%
Perf Quarter	-96.79%
Perf Half Y	-97.29%
Perf YTD	-97.95%
Perf Year	-97.14%
Perf 3Y	-94.86%
Perf 5Y	-96.94%
Perf 10Y	-98.04%
Recom	2.54
Target Price	12.39
Prev Close	0.35
Price	0.37
Change %	7.58%

Consensus

Hold

Avg. Price Target

$12.39

Implied Upside

+3,205.8%

Analysts14incl. previous ratings

Rating Distribution5 Buy · 8 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Downgrade	MMizuho	Outperform → Neutral	$0.50	+33.4%
Oct 20, 2026	Downgrade	JJP Morgan	Neutral → Underweight
Oct 19, 2026	Downgrade	JJefferies	Buy → Hold	$1	+166.8%
Oct 19, 2026	Downgrade	GGuggenheim	Buy → Neutral
Sep 02, 2026	Downgrade	TTD Cowen	Buy → Hold	$4	+967.2%
Aug 18, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$5	+1,234.0%
Aug 18, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Aug 18, 2026	Downgrade	CChardan Capital Markets	Buy → Neutral	$5	+1,234.0%
Aug 17, 2026	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jul 16, 2026	Initiated	SStifel	Buy	$40	+10,572.4%
Jul 08, 2026	Resumed	CCantor Fitzgerald	Overweight	$47	+12,440.0%
Jun 17, 2025	Initiated	RRBC Capital Mkts	Outperform	$28	+7,370.7%
Jan 07, 2025	Initiated	CCitigroup	Buy	$33	+8,704.7%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Aug 28, 2024	Initiated	JJefferies	Buy	$15	+3,902.1%
Jan 22, 2024	Initiated	JJP Morgan	Overweight	$35	+9,238.3%
Nov 02, 2023	Initiated	MMizuho	Buy	$20	+5,236.2%
Apr 21, 2023	Initiated	RRobert W. Baird	Outperform	$33	+8,704.7%
Jul 07, 2022	Initiated	CChardan Capital Markets	Buy	$21	+5,503.0%
Mar 01, 2021	Initiated	CCowen	Outperform	$25	+6,570.2%

Oct-20-26 07:37AM	EyePoint halves workforce and ends Phase III trial early after endpoint miss (Clinical Trials Arena) -7.91%
Oct-19-26 10:39PM	Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today? (Stocktwits) -85.28%
09:58AM	EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut (Investing.com)
08:47AM	EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results (InvestorsHub)
08:19AM	This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope. (Barrons.com)
07:15AM	Loading…
07:15AM	EyePoint Announces Strategic Prioritization (GlobeNewswire)
07:00AM	EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU in Wet AMD (GlobeNewswire)
Sep-28-26 01:15PM	OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits) -8.56%
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
Sep-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.74%
Sep-06-26 06:30AM	Street Calls of the Week (Investing.com)
Sep-02-26 09:54AM	Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting (GlobeNewswire)
Aug-24-26 08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com) -8.46%
Aug-18-26 10:40AM	EyePoints Duravyu falls short to Eylea in Phase III trial (Clinical Trials Arena) +12.32%
09:37AM	Loading…
09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly)
07:57AM	EyePoints Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says Retail Calls EYPT Slump A Huge Overreaction (Stocktwits)
Aug-17-26 11:00PM	Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -66.98%
07:51PM	OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits)
11:14AM	EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. (Barrons.com)
10:56AM	EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden (InvestorsHub)
09:41AM	The Surprising Reason EyePoint Just Crashed 69% (Investor's Business Daily)
09:19AM	EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback Retail Sees Ocular Therapeutics As A Better Buyout Candidate (Stocktwits)
07:00AM	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD (GlobeNewswire)
Aug-14-26 04:32PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +9.42%
Aug-05-26 07:33AM	EyePoint: Q2 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-30-26 07:00AM	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire) +7.89%
Jul-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.85%
Jul-13-26 07:00AM	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer (GlobeNewswire)
07:00AM	Loading…
Jun-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.62%
May-19-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-18-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.26%
May-14-26 07:00AM	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data (GlobeNewswire)
May-06-26 07:21AM	EyePoint: Q1 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-29-26 07:00AM	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Apr-16-26 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	Director	Aug 18 '26	Buy	4.93	10,600	52,258	49,100	Aug 18 04:08 PM
Lurker Nancy	Officer	Jul 21 '26	Proposed Sale	13.05	421,235	5,497,117		Jul 21 04:44 PM
Duker Jay S.	President and CEO	Jul 10 '26	Option Exercise	0.00	16,667	0	17,653	Jul 14 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Option Exercise	8.26	4,875	40,268	4,875	Jul 02 04:03 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Sale	15.01	4,875	73,167	0	Jul 02 04:03 PM
Elston George	Chief Financial Officer	May 25 '26	Option Exercise	0.00	7,500	0	95,318	May 27 04:05 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Apr 20 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Sale	15.00	2,437	36,555	0	Apr 20 04:07 PM
Ramiro Ribeiro	Officer	Apr 17 '26	Proposed Sale	14.81	9,750	144,398		Apr 17 04:36 PM
Duker Jay S.	President and CEO	Mar 16 '26	Buy	13.15	1,500	19,724	100,665	Mar 16 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

PresidentDr. Jay S. Duker M.D.

Executive VP & CFOMr. George O. Elston CPA

Ph.D.Dr. Ramiro Ribeiro M.D.

Chief Scientific OfficerDr. Marcia Sellos-Moura Ph.D.

Chief Legal Officer & Company SecretaryMr. Ron I. Honig Esq.

Open in Screener

OKUR

OnKure Therapeutics Inc

2.59

Nov 02 • 3:59 PM ET -0.03 (-1.15%)

2.59

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

OKUR OnKure Therapeutics Inc daily Stock Chart

Peers: RLAY CELC OLMA KZIA ARVN BDTX PVLA ACRV ZNTL TYRA

| Held by: VTI IWM VXF IWN VTWO TMED IWC BUSM DFAS AVSC

Index	RUT
Market Cap	104.89M
Enterprise Value	-70.57M
Income	-58.70M
Sales	0.00M
Book/sh	4.25
Cash/sh	4.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	45
IPO	Apr 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.61
P/C	0.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	26.75
Current Ratio	26.75
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.50
EPS next Y	-1.53
EPS next Q	-0.41
EPS this Y	59.24%
EPS next Y	14.87%
EPS next 5Y	32.97%
EPS past 3/5Y	40.79% 11.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	34.92%
Sales Y/Y TTM	-
EPS Q/Q	72.99%
Sales Q/Q	-
Earnings	Aug 04 AMC
EPS/Sales Surpr.	42.06% -100.00%

Insider Own	31.26%
Insider Trans	-0.01%
Inst Own	71.73%
Inst Trans	12.94%
ROA	-44.24%
ROE	-46.91%
ROIC	-33.99%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.24%
SMA50	-10.04%
SMA200	-28.25%
Trades

Shs Outstand	40.50M
Shs Float	27.84M
Short Float	4.98%
Short Ratio	5.17
Short Interest	1.39M
52W High	5.38 -51.86%
52W Low	2.01 28.86%
Volatility	8.75% 8.51%
ATR (14)	0.21
RSI (14)	49.46
Beta	0.18
Rel Volume	1.87
Avg Volume	267.77K
Volume	500,741

Perf Week	4.65%
Perf Month	1.17%
Perf Quarter	-36.83%
Perf Half Y	-43.70%
Perf YTD	-10.69%
Perf Year	-23.60%
Perf 3Y	-96.74%
Perf 5Y	-96.35%
Perf 10Y	-
Recom	1.50
Target Price	13.67
Prev Close	2.62
Price	2.59
Change %	-1.15%

Consensus

Buy

Avg. Price Target

$13.67

Implied Upside

+427.8%

Analysts11incl. previous ratings

Rating Distribution4 Buy · 6 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 30, 2025	Initiated	EEvercore ISI	Outperform
Dec 05, 2024	Initiated	LLeerink Partners	Outperform	$33	+1,174.1%
Oct 10, 2024	Initiated	OOppenheimer	Outperform	$35	+1,251.4%
Dec 15, 2023	Downgrade	LLeerink Partners	Outperform → Market Perform
Dec 15, 2023	Downgrade	JJefferies	Buy → Hold
Dec 15, 2023	Downgrade	HH.C. Wainwright	Buy → Neutral	$30 → $1.50	-42.1%
Dec 14, 2023	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Dec 14, 2023	Downgrade	RRobert W. Baird	Outperform → Neutral	$28 → $3	+15.8%
Dec 14, 2023	Downgrade	PPiper Sandler	Overweight → Neutral	$25 → $4	+54.4%
Dec 14, 2023	Downgrade	LLadenburg Thalmann	Buy → Neutral
Dec 14, 2023	Downgrade	BBofA Securities	Buy → Underperform	$23 → $1.45	-44.0%
Nov 15, 2023	Initiated	WWilliam Blair	Outperform	$35.55	+1,272.6%
Aug 28, 2023	Initiated	HH.C. Wainwright	Buy	$30	+1,058.3%
Jul 03, 2023	Initiated	BBofA Securities	Buy
Sep 19, 2022	Resumed	HH.C. Wainwright	Buy	$31	+1,096.9%
Jan 27, 2022	Initiated	RRobert W. Baird	Outperform	$28	+981.1%
Dec 21, 2021	Initiated	HH.C. Wainwright	Buy	$28	+981.1%
Nov 22, 2021	Initiated	LLadenburg Thalmann	Buy	$45	+1,637.5%
May 04, 2021	Initiated	SSVB Leerink	Outperform	$25	+865.3%
May 04, 2021	Initiated	PPiper Sandler	Overweight	$45	+1,637.5%

Aug-31-26 08:00AM	OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-04-26 04:05PM	OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-02-26 08:00AM	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 (GlobeNewswire)
May-05-26 04:05PM	OnKure Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -9.96%
Mar-27-26 08:00AM	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies (GlobeNewswire) -13.07%
04:05PM	Loading…
Mar-12-26 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +7.39%
Nov-06-25 04:03PM	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +5.33% -6.96%
Nov-04-25 04:05PM	OnKure Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.20%
Aug-12-25 04:05PM	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +20.00%
May-06-25 07:30AM	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
Mar-10-25 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:00AM	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
Dec-10-24 07:00AM	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%
Nov-25-24 05:31PM	OnKure Announces New Date for Upcoming Investor Call (GlobeNewswire)
Nov-05-24 04:05PM	OnKure to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +7.90%
05:30PM	Loading…
Nov-01-24 05:30PM	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.91%
Oct-07-24 04:32AM	OnKure and Reneo Pharmaceuticals complete merger (Pharmaceutical Technology)
Oct-04-24 04:57PM	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million (GlobeNewswire) +5.20%
Oct-02-24 08:20PM	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure (GlobeNewswire)
Aug-13-24 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 10:01AM	Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing (MT Newswires)
May-13-24 08:25AM	Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise (MT Newswires) -12.15%
07:35AM	Reneo Pharmaceuticals and OnKure Announce Proposed Merger (GlobeNewswire)
May-07-24 01:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 12:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update (GlobeNewswire)
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
Dec-15-23 10:19AM	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study (Zacks) +5.97%
12:35PM	Loading…
Dec-14-23 12:35PM	Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? (Benzinga) -82.71%
09:05AM	Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Nov-13-23 05:04PM	Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:50AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 07:50AM	Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey) -5.76%
Oct-09-23 07:50AM	Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Oct-06-23 08:30AM	Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +11.47%
Aug-29-23 07:35AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.30%
Aug-10-23 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:31AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy (Simply Wall St.)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) +17.59%
Jun-30-23 08:25AM	Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 08:25AM	Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices (GlobeNewswire)
Jun-15-23 12:44PM	Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 (GlobeNewswire)
May-31-23 10:38AM	Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-21-23 07:42PM	Insiders Pour $1 Million Each Into These 2 Strong Buy Stocks Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
May-12-23 06:00PM	MP Materials, Pitney Bowes See Activist Investor Action (Barrons.com)
May-11-23 07:45AM	Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire) +6.02%
May-03-23 11:36PM	Reneo Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies (GlobeNewswire)
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 (GlobeNewswire)
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week (Simply Wall St.)
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) (GlobeNewswire)
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week (Simply Wall St.) +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting (GlobeNewswire)
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m (Simply Wall St.) +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors (GlobeNewswire) -15.92%
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development (Benzinga)
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates (GlobeNewswire)
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) (GlobeNewswire) +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire) +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions (GlobeNewswire)
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference (GlobeNewswire) -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors (GlobeNewswire)
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.)
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential (TipRanks) +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results (GlobeNewswire) +9.08% +5.23%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 (GlobeNewswire)
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer (GlobeNewswire)
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies (GlobeNewswire)
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study (GlobeNewswire)
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.) +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction (GlobeNewswire)
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices (GlobeNewswire)
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results (GlobeNewswire) +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug (Benzinga)
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today (InvestorPlace)
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saccomano Nicholas A	President and CEO	Sep 21 '26	Sale	2.97	87	259	11,160	Sep 23 04:54 PM
Leverone Jason A.	Chief Financial Officer	Sep 21 '26	Sale	2.97	302	898	18,500	Sep 23 04:52 PM
Saccomano Nicholas A	President and CEO	Jun 22 '26	Sale	4.40	86	378	11,247	Jun 24 07:29 PM
Leverone Jason A.	Chief Financial Officer	Jun 22 '26	Sale	4.40	303	1,332	18,802	Jun 24 07:27 PM
Saccomano Nicholas A	President and CEO	Mar 23 '26	Sale	4.16	86	357	7,333	Mar 24 06:57 PM
Leverone Jason A.	Chief Financial Officer	Mar 23 '26	Sale	4.16	301	1,251	16,000	Mar 24 06:56 PM
Saccomano Nicholas A	President and CEO	Dec 22 '25	Sale	2.97	87	258	7,419	Dec 23 08:09 PM
Leverone Jason A.	Chief Financial Officer	Dec 22 '25	Sale	2.97	302	896	16,301	Dec 23 08:08 PM

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

PresidentDr. Nicholas A. Saccomano Ph.D.

Chief Financial OfficerMr. Jason A. Leverone CPA

Senior VP of Business Development & DirectorDr. Isaac Manke Ph.D.

M.P.H.Dr. Samuel Agresta M.D.

Chief Scientific OfficerDr. Dylan Hartley Ph.D.

Open in Screener

AARD

Aardvark Therapeutics Inc

1.20

Nov 02 • 3:59 PM ET -0.16 (-11.76%)

1.25

Aftermarket • 7:30 PM ET +0.05 (4.17%)

Healthcare Biotechnology USA Nano NASD

AARD Aardvark Therapeutics Inc daily Stock Chart

Peers: RYTM HRMY ACAD CRBP PTN ALT GPCR SKYE VKTX AMLX

| Held by: VTI VXF IBB IWC BUSM DXUV IBBQ DFMC BIB

Index	-
Market Cap	26.26M
Enterprise Value	-46.93M
Income	-69.89M
Sales	0.00M
Book/sh	3.42
Cash/sh	3.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Feb 13, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.35
P/C	0.36
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.63
Current Ratio	12.63
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.21
EPS next Y	-2.36
EPS next Q	-0.72
EPS this Y	-5.15%
EPS next Y	23.46%
EPS next 5Y	8.96%
EPS past 3/5Y	-60.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-89.45%
Sales Y/Y TTM	-
EPS Q/Q	0.56%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	24.52% -

Insider Own	41.42%
Insider Trans	-0.84%
Inst Own	25.21%
Inst Trans	-6.94%
ROA	-61.06%
ROE	-66.02%
ROIC	-93.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-62.94%
SMA50	-74.26%
SMA200	-80.80%
Trades

Shs Outstand	21.88M
Shs Float	12.82M
Short Float	4.32%
Short Ratio	0.95
Short Interest	0.55M
52W High	16.60 -92.77%
52W Low	0.93 29.03%
Volatility	26.87% 20.05%
ATR (14)	0.51
RSI (14)	23.97
Beta	4.37
Rel Volume	0.59
Avg Volume	584.55K
Volume	343,546

Perf Week	11.11%
Perf Month	-75.95%
Perf Quarter	-83.40%
Perf Half Y	-77.23%
Perf YTD	-90.86%
Perf Year	-88.77%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.36
Target Price	7.50
Prev Close	1.36
Price	1.20
Change %	-11.76%

Consensus

Buy

Avg. Price Target

$7.50

Implied Upside

+525.0%

Analysts11incl. previous ratings

Rating Distribution7 Buy · 3 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 15, 2026	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$3	+150.0%
Mar 02, 2026	Downgrade	SStifel	Buy → Hold	$6	+400.0%
Mar 02, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$6	+400.0%
Mar 02, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$7	+483.3%
Mar 02, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Jan 28, 2026	Initiated	RB. Riley Securities	Buy	$32	+2,566.7%
Dec 23, 2025	Initiated	OOppenheimer	Outperform	$35	+2,816.7%
Dec 12, 2025	Initiated	WWilliam Blair	Outperform
Dec 03, 2025	Initiated	RRaymond James	Strong Buy	$47	+3,816.7%
Nov 07, 2025	Initiated	BBTIG Research	Buy	$26	+2,066.7%
Sep 29, 2025	Initiated	SStifel	Buy	$24	+1,900.0%
Jun 30, 2025	Initiated	HH.C. Wainwright	Buy	$40	+3,233.3%
Mar 10, 2025	Initiated	RRBC Capital Mkts	Outperform	$21	+1,650.0%
Mar 10, 2025	Initiated	MMorgan Stanley	Overweight	$29	+2,316.7%
Mar 10, 2025	Initiated	CCantor Fitzgerald	Overweight	$50	+4,066.7%
Mar 10, 2025	Initiated	BBofA Securities	Buy	$22	+1,733.3%

Oct-23-26 07:00AM	Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials (GlobeNewswire) -64.81%
Oct-22-26 05:57PM	Aardvark Therapeutics stock surges as FDA lifts clinical hold (Investing.com) -10.43%
04:05PM	Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data (GlobeNewswire)
Oct-12-26 02:29AM	Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD (PR Newswire) -6.51%
Oct-08-26 08:00AM	Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors (GlobeNewswire) -5.04%
12:15PM	Loading…
Oct-05-26 12:15PM	If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
Oct-02-26 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.31%
Sep-17-26 03:25PM	Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 (Newsfile) +7.38%
Sep-04-26 05:21PM	AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) -6.11%
Aug-25-26 09:02AM	Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately (PR Newswire) +5.38%
Aug-24-26 01:01PM	Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD (Newsfile)
Aug-17-26 01:31PM	Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
Aug-11-26 04:53PM	Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%
Jul-22-26 04:00PM	Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman (PR Newswire) +6.58%
Jun-25-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
09:00AM	Loading…
Jun-19-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
May-21-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire) +5.13%
May-15-26 07:58AM	FDA hold puts Aardvark Prader-Willi drug in limbo (BioPharma Dive) -32.10%
May-14-26 04:01PM	Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold (GlobeNewswire)
May-07-26 08:00AM	Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-10-26 04:17PM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman (PR Newswire)
Mar-23-26 04:05PM	Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.26%
Mar-04-26 08:54AM	What's Going On With Aardvark Therapeutics Stock On Wednesday? (Benzinga) +15.10%
Mar-02-26 09:49AM	Why Aardvark Therapeutics Just Lost More Than Half Its Value (Investor's Business Daily) -56.20%
07:02AM	Why Is Aardvark Therapeutics Stock Sinking Monday? (Benzinga)
05:23AM	Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran- AMTD Digital, Aardvark, MongoDB In Focus (Benzinga)
03:26AM	Safety concerns spur Aardvark to halt key Prader-Willi drug trial (BioPharma Dive)
Feb-27-26 04:05PM	Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome (GlobeNewswire)
Feb-13-26 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-26 08:00AM	Aardvark Therapeutics Announces Leadership Appointments (GlobeNewswire)
08:00AM	Loading…
08:00AM	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer (GlobeNewswire)
Feb-10-26 08:00AM	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome (GlobeNewswire) -6.45%
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66% -7.56%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Nelson	See Remarks	Sep 11 '26	Sale	5.18	62,000	321,179	35,475	Sep 11 08:14 PM
Sun Nelson	See Remarks	Sep 10 '26	Sale	5.00	14,754	73,779	97,475	Sep 11 08:14 PM
NELSON SUN	Officer	Sep 11 '26	Proposed Sale	5.01	33,911	169,894		Sep 11 04:51 PM
NELSON SUN	Officer	Sep 10 '26	Proposed Sale	4.92	42,843	210,788		Sep 10 05:18 PM
Sun Nelson	Chief Financial Officer	Dec 11 '25	Buy	14.40	3,000	43,200	108,484	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Dec 11 '25	Buy	14.48	7,000	101,395	1,551,613	Dec 12 08:30 PM

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

CEODr. Tien-Li Lee M.D.

CFO & COOMr. Nelson B. Sun M.B.A.

M.P.H.Dr. Manasi Sinha Jaiman M.D.

Executive Vice President of Medical AffairsDr. Dvorit Samid Ph.D.

Chief Research OfficerDr. Zhenhuan Zheng Ph.D.

CRBP

Corbus Pharmaceuticals Holdings Inc

DRUG

Bright Minds Biosciences Inc

EYPT

EyePoint Inc

OKUR

OnKure Therapeutics Inc

AARD

Aardvark Therapeutics Inc

Upgrade your Finviz experience